ArticleNutrients2025
PLX3397-Induced Microglial Ablation Alters Adipose Tissue Accumulation in a Male-Female-Dependent Manner Under High-Energy-Diet Feeding.
Article in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundDiet-induced obesity (DIO) is increasingly linked to microglial proliferation in the central nervous system, yet the causal role of microglia in metabolic and behavioral changes remains unclear.
methodsHere, we investigated the effects of microglial suppression using the CSF-1R antagonist PLX 3397 (Pexidartinib; PLX) on body weight, adiposity, and sucrose preference in lean and DIO male and female rats. Microglial activation was quantified in the hypothalamus and nucleus tractus solitarius (NTS).
resultsPLX administered during initial high-energy-diet (HED) exposure produced sex-specific effects: body weight increased in males but decreased in females. In male DIO rats, PLX+HED reduced body fat percentage without altering total weight. PLX treatment did not significantly alter body weight, food intake, or glucose tolerance in females. Hypothalamic microglial suppression was more extensive in males, whereas NTS suppression was similar across sexes. PLX also reversed HED-induced reductions in low-concentration sucrose preference in males. Substantial individual variability was observed in both susceptibility to DIO and responsiveness to PLX.
conclusionsThese findings reveal a clear sexual dimorphism in microglial responses to HED, with females showing relative protection and males' greater vulnerability. Overall, the results underscore the importance of accounting for sex differences in the design and application of microglia-targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.